Selegiline is a medication used to treat Parkinson's disease and depression. It works by helping to increase levels of a chemical messenger in the brain called dopamine. This helps improve symptoms like tremors and stiffness in Parkinson's, and can help lift mood in depression.
Every report comes from a Lived member, sent anonymously.
Have you tried Selegiline for Parkinson's Disease?
Selegiline is a prescription medicine that blocks monoamine oxidase (MAO), an enzyme that breaks down several of the brain's chemical messengers. It is used in two quite different ways, and the form of the medicine decides the use. As a tablet or capsule, selegiline is an add-on treatment for Parkinson's disease in people already taking levodopa/carbidopa whose doses have started to work less well, for example wearing off before the next dose is due. It was once sold under the brand name Eldepryl, which is no longer marketed in the US; generic tablets and capsules remain available. A tablet that dissolves on the tongue, Zelapar, has also been discontinued in the US. The US label states there is no controlled evidence that oral selegiline helps without levodopa, although some doctors use this drug family on its own early in Parkinson's for mild symptoms, accepting a weaker effect than levodopa. As a skin patch sold as Emsam, selegiline is an antidepressant approved for major depressive disorder in adults. It belongs to the MAO inhibitor (MAOI) family of antidepressants, which call for care with certain foods and with many other medicines.
MAO comes in two types. Most of the MAO in the brain is type B (MAO-B), which helps break down dopamine, the chemical messenger that runs low in Parkinson's disease. Type A (MAO-A) is plentiful in the gut and liver, where it also clears tyramine, a substance in some aged and fermented foods that can sharply raise blood pressure if it reaches the bloodstream intact. At the doses used for Parkinson's disease, selegiline mainly blocks MAO-B, so dopamine, including dopamine the brain makes from levodopa, lasts longer. That helps smooth out levodopa's effect and can allow a lower levodopa dose. This selectivity is not complete, and it fades as the dose rises, which is why the oral dose has a firm ceiling. Selegiline treats symptoms; whether it slows Parkinson's disease itself has been studied, with conflicting results. At the doses used for depression, the patch blocks both MAO-A and MAO-B in the brain, raising levels of serotonin, norepinephrine and dopamine. Exactly how this relieves depression is not fully understood, and the full antidepressant effect is often delayed.
For Parkinson's disease, the usual oral dose is 5 mg twice a day, taken at breakfast and lunch, for a total of 10 mg a day. Higher doses add no proven benefit and should not be used: above that level selegiline starts blocking MAO-A as well, and the risk of a dangerous blood pressure reaction rises. Because selegiline strengthens levodopa's effects and side effects, the prescriber may lower the levodopa/carbidopa dose within a few days of starting, often by 10 to 30 percent. The Emsam patch is worn for 24 hours and then replaced with a new one, at about the same time each day. It goes on clean, dry, unbroken skin on the upper body between the neck and waist, the upper thigh or the outer upper arm, using a different spot each day. It comes in 6, 9 and 12 mg strengths, meaning the amount delivered over 24 hours. Treatment usually starts at 6 mg, and any increase is made in 3 mg steps at least two weeks apart; people 65 and older are generally kept at 6 mg. Keep direct heat off the patch, such as heating pads, electric blankets, heat lamps, saunas, hot tubs and long stretches of direct sun, since heat may increase how much medicine is absorbed. The 6 mg patch does not require a special diet. Oral selegiline at 10 mg a day usually does not either, although rare reactions to tyramine-rich foods have been reported. On the 9 or 12 mg patch, foods and drinks high in tyramine must be avoided from the first day and for two weeks after lowering the dose to 6 mg or stopping. These include aged cheeses, air-dried or fermented meats such as salami, tap or unpasteurized beer, sauerkraut, soy sauce and most soybean products, concentrated yeast extracts such as Marmite, fava bean pods, tyramine-containing supplements, and any spoiled meat or fish. Fresh meat and fish, fresh cheeses such as mozzarella and cottage cheese, yogurt, and bottled or canned beer and wine contain little or no tyramine, although drinking alcohol is not recommended with Emsam.
With the Emsam patch, the most common side effect is redness or irritation where the patch was worn, reported by about a quarter of people in trials compared with about one in eight on a placebo patch. It is usually mild. Headache, trouble sleeping, diarrhea, dry mouth and indigestion are also common, and some people feel lightheaded when standing up because of a drop in blood pressure. In Parkinson's disease, oral selegiline most often causes nausea, dizziness or lightheadedness, dry mouth, confusion, vivid dreams and hallucinations. Because it boosts levodopa, it can also worsen existing levodopa side effects, especially dyskinesia (involuntary twisting or jerking movements); lowering the levodopa dose often helps. Two effects in Parkinson's disease are easy to miss and worth raising even when they feel awkward. Medicines that increase dopamine activity, selegiline among them, can cause strong, hard-to-control urges to gamble, spend money, eat or have sex; these sometimes ease when the dose is lowered or stopped, and family members often notice first. They can also cause sudden sleepiness, including falling asleep while driving, sometimes without warning. Tell the prescriber about either, and do not drive if a sudden sleep episode has happened.
Selegiline's most serious risks come from combining it with other medicines. Taken with drugs that raise serotonin, it can cause serotonin syndrome, a potentially life-threatening reaction. Combinations to avoid include selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressants such as sertraline, fluoxetine and duloxetine; tricyclic antidepressants; the opioid pain medicines meperidine, tramadol and methadone; dextromethorphan, the cough suppressant in many cold remedies; and the herbal supplement St. John's wort. Selegiline also must not be combined with another MAO inhibitor, including the Parkinson's medicines rasagiline (Azilect) and safinamide (Xadago) and the antibiotic linezolid, because doubling up raises the risk of both serotonin syndrome and a dangerous rise in blood pressure. These restrictions continue after stopping. At least two weeks should pass after stopping selegiline before starting any of these drugs. Before starting either form of selegiline, at least five weeks should pass after stopping fluoxetine. Before starting the patch, about a week should pass after stopping most of the others. Carbamazepine (a seizure and mood medicine) must not be used with Emsam, because it raises selegiline levels in the blood and with them the risk of a dangerous rise in blood pressure. Decongestants such as pseudoephedrine and phenylephrine, found in many cold and sinus products, amphetamine-type stimulants and buspirone (an anti-anxiety medicine) can also raise blood pressure substantially with Emsam, so they should not be started without the prescriber's agreement and blood pressure monitoring. Check with the prescriber or pharmacist before starting any new prescription, over-the-counter product or supplement. A sudden severe headache, often starting at the back of the head, a stiff or sore neck, a pounding or racing heartbeat, chest pain, or heavy sweating with nausea or vomiting can signal a hypertensive crisis, a dangerous spike in blood pressure. Get emergency medical care right away. Confusion or agitation together with high fever, muscle stiffness or jerking, and a fast heartbeat can signal serotonin syndrome and also needs emergency care. Like other antidepressants, Emsam carries a boxed warning, the strongest caution from the US Food and Drug Administration (FDA): in short-term studies, antidepressants increased suicidal thoughts and behaviors in children, teenagers and young adults. People starting the patch or changing the dose, and those close to them, should watch for worsening depression, agitation or new suicidal thoughts and contact the prescriber promptly if they appear. Emsam must not be used in children under 12 and is not recommended for teenagers. Before starting, people should be checked for a personal or family history of bipolar disorder, since an antidepressant can trigger mania, and Emsam is not used in people with pheochromocytoma, a rare adrenal tumor. Information on use in pregnancy is limited, so pregnancy plans need discussion, and breastfeeding is not recommended during treatment or for five days after the last patch.
In Parkinson's disease, selegiline's effect is modest. People typically notice less off time, meaning fewer stretches when levodopa has worn off and movement becomes slow or stiff, and some can manage on a lower levodopa dose. It does not replace levodopa. When used alone early in the disease, its effect on symptoms is weaker than that of levodopa or dopamine agonists (medicines that act like dopamine, such as pramipexole), and people more often need another medicine added over time. Changes to Parkinson's medicines, including stopping selegiline, should be planned with the prescriber; quickly reducing or stopping antiparkinson treatment has rarely caused high fever, muscle rigidity and confusion. With the patch for depression, improvement builds gradually and the full effect can take a while to appear. If depression lifts, treatment usually continues for months, because episodes of depression generally need several months or longer of treatment, and the prescriber periodically reviews whether to continue. Because selegiline disables the MAO enzyme until the body makes more, the food and drug precautions described above outlast the last patch. Ongoing care for either use includes blood pressure checks, a regular review of every medicine and supplement, and routine skin checks, ideally by a dermatologist. Melanoma is more common in people with Parkinson's disease, and it is unclear whether the disease or its medicines are responsible, so the label advises regular skin checks for anyone taking selegiline.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Selegiline, what you've noticed, or ask the community a question.